Berke­ley Lights to ac­quire Iso­Plex­is in $57.8M all-stock deal

3 years ago
Deals

Eli Lil­ly ties up 2022 by ex­pand­ing deal with bat­tered RNA-edit­ing biotech

3 years ago
Deals
R&D

Back again: Mer­ck will­ing to dole out more than $9B for Kelun’s AD­Cs

3 years ago
Deals
China

Rid­ing on pos­i­tive PhI­II NASH da­ta, Madri­gal rais­es $300M for road to FDA

3 years ago
Financing

Alex Hard­ing to chase in­dus­try dreams at CRISPR Ther­a­peu­tics; Scoop: Bio­gen’s head of busi­ness de­vel­op­ment splits ...

3 years ago
Peer Review

Catch­ing up in mul­ti­ple myelo­ma, Pfiz­er taps ORIC for BC­MA com­bo study

3 years ago
R&D

BioSpring in­vests €100M+ in­to new oligonu­cleotide API fa­cil­i­ties in Ger­many

3 years ago
Pharma
Manufacturing

Vir­ginia Rep. Span­berg­er asks FDA, DEA chiefs to re­spond to Adder­all short­ages

3 years ago
Pharma
FDA+

Up­dat­ed: BioN­Tech sends mR­NA Covid-19 vac­cines to Chi­na for 20,000 ex­pats

3 years ago
Coronavirus

New year, new hire: Mod­er­na taps Mer­ck vet­er­an as lat­est com­mer­cial ex­ec

3 years ago
Pharma
Marketing

CBER's Pe­ter Marks says Covid-19 shots to mir­ror flu shots: Man­u­fac­tur­ers will be in­ter­change­able

3 years ago
FDA+
Coronavirus

FDA and EMA ac­cept Pfiz­er’s reg­u­la­to­ry sub­mis­sions for ul­cer­a­tive col­i­tis drug

3 years ago
R&D
FDA+

Zyner­ba cites 'triple­demic' for PhI­II de­lay of a cannabi­noid drug that's failed mul­ti­ple times

3 years ago
R&D

Every­one wants in on GLP-1: Pfiz­er dos­es first pa­tient in PhII tri­al for di­a­betes and obe­si­ty drug, pays So­sei $10M

3 years ago
R&D

Zymeworks sings to the tune of $325M with Jazz opt-in for HER2 can­cer drug

3 years ago
Deals
R&D

TG's MS hope­ful ubli­tux­imab not cost-ef­fec­tive at Ocre­vus' price, ICER says in ev­i­dence re­port

3 years ago
Pharma

Celyad scraps one fi­nal clin­i­cal CAR-T pro­gram as clock ticks

3 years ago
R&D
Cell/Gene Tx

Health­Care Roy­al­ty pays Atara $31M cash for a piece of cell ther­a­py roy­al­ties in Eu­rope

3 years ago
Deals

'As the mar­ket has turned': Enve­da se­cures $68M to move re­vised pipeline in­to the clin­ic in 2023

3 years ago
Financing
Startups

Af­ter PhII re­sults dis­ap­point, Mer­ck ex­cis­es eye drugs from long­time pact with NGM

3 years ago
Deals

Cor­rect­ed: Fac­ing decades in prison, two biotech lead­ers charged with wire and se­cu­ri­ties fraud, ly­ing to ...

3 years ago
Pharma
FDA+

Up­dat­ed: Sev­er­al man­u­fac­tur­ers re­port Tam­i­flu short­age as flu sea­son reach­es high point

3 years ago
Pharma
Manufacturing

Ahead of lecanemab de­ci­sion, Alzheimer's groups pe­ti­tion CMS to re­verse cov­er­age pol­i­cy

3 years ago
Pharma

Re­al Chem­istry's hol­i­day gift to clients: fight­ing hate speech

3 years ago
Pharma
Marketing
First page Previous page 410411412413414415416 Next page Last page
A service from the Financial Times